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A Study of Complicated Falciparum Malaria and Efﬁcacy
of Arteether in Children in Endemic Area of India
M.L. Sharma
WHO NPSP India, Bikaner, India
Malaria has re-emerged as main public health problems.
In tropical countries resulting in signiﬁcant morbidity and
mortality. Plasmodium falciparum is responsible for poten-
tially fatal infections.
Aims and Objectives:
(1) To evaluate the efﬁcacy of Arteether in the treatment
of complicated malaria
(2) To analyze clinical spectrum of hospitalized cases of
falciparum and virex malaria.
Material and Methods: The study at Urban Private
Hospital Patients with pyrexia and slides positive for P.
falciparum. Out of 75 patients 24 were children with com-
plicated malaria. A dose of Arteether (2.5mg/Kg.) once
daily by intra-muscular injection for 3 consecutive days,
patients remained hospitalised,the therapeutic response
was assessed on clinical parameter and smears for parasites.
Results: Out of 75 smear positive 24 children of com-
plicated malaria. 1 to 17 year age, clinical symptoms
fever, hyperpyrexia 100%, vomiting 40%, headache 15%,
icterus 35%, alerted sensorium 25%, oligourea 10%, bleed-
ing 5% weakness, bodyache, loss of appetite,insomnia.
Splenomegaly and hepatomegaly > 2 cm in 82% and 78%.
serum bilirubin > 3mg% and elevated SGOT, SGPT > 3
times, serum cretanin > 3mg% and blood urea > 40mg%
renal failure. Severe anaemia Hb < 5mg%. Complicated
falciparum malaria with jaundice and hepatic dysfunc-
tion.33.3%,cerebral malaria 25%, renal failure 13.3%,
haemoglobinria 0.4%, severe anemia with symptomic
involvement 33.3%.
The therapuetic response was assessed on clinical param-
eters and smears for parasites. Level of consciousness
started improving with in 24—48 hours and full consciousness
48 to 72 hour Fever clearance 24 to 48 hours. Serum bilirubin
levels start decreasing 3 days normal within 7-days. Serum
creatinine normal within 7 days Anemia in children with
arteether patient responded well. Splenomegaly regressed
in one month, parasitic clearance with arteether within 2
days, in 22 patients four week 92% of cure rate in compli-
cated P. falciparum malaria.
doi:10.1016/j.ijid.2008.05.830
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The Effect of Cyclic Adenosine Monophosphate (cAMP)
Modulators on the Activity of Selected Anti-Malaria Drugs
J. Wangui1,∗, J.J.N. Ngeranwa2, H. Akala1, N.C. Waters3
1 USAMRU-K, Nairobi, Kenya
2 Kenyatta University, Nairobi, Kenya
3 Australian Army Malaria Institute, Enoggera, Australia
Background: Malaria is a major global health prob-
lem with high mortality rates especially in children below
ﬁve years of age. A severe limitation of chemotherapy is
the rapid emergence of resistance to most available anti-
malarials. Because of the slow development of new effective
anti-malarials, an alternative strategy is therapy optimiza-
tion using existing drugs. Combination therapy has been
shown to delay the onset of resistance and improve the
efﬁcacy of treatment. This study’s objective was to estab-
lish the activity of several cyclic Adenosine Monophosphate
(cAMP) modulators as potential components of combination
therapy.
Methods: The cAMP modulators; forskolin, Sp-adenosine
3′ 5 cyclic monophosphorothiate triethylammonium salt, 9-
cyclopentyladenine and 2′ 5′ dideoxyadenosine 3′ monophos-
phate were tested in vitro in combination with chloroquine,
quinine, meﬂoquine, amodiaquine and doxycycline against
the chloroquine sensitive strain (D6) and the chloroquine
resistant strain (W2) of Plasmodium falciparum. Parasite sus-
ceptibility testing was performed using a semi-automated
micro-dilution technique. The Inhibitory Concentration at
50% (IC50) was calculated for each drug and in ﬁxed com-
binations. Isobolograms were plotted using the calculated
Fractional Inhibitory Concentration at 50% (FIC50).
Results: One of the AC-inhibitors, in combination with
quinine showed synergistic interactions at all concentration
ratios for both the D6 and W2 strains (FIC50s < 0.92 at all
concentrations). The other anti-malarial/cAMP modulator
combinations demonstrated a range of responses but mainly
exhibited antagonistic interactions.
Conclusion: These in vitro ﬁndings suggest that the AC
inhibitor, 2′ 5′ dideoxyadenosine 3′ monophosphate, poten-
tially enhanced the anti-malarial activity when combined
with quinine and should be further evaluated. The other
anti-malarial/cAMP Modulator combinations did not show
the same potential.
doi:10.1016/j.ijid.2008.05.831
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IgG Proﬁle Against MSP3 Antigen in Asymptomatic Carriers
of Plasmodium faliciparum in Eastern Sudan
A. Gadalla1,∗, S. El-Zaki1, N. Gadalla1, I. Mukhtar1, T.
Ageep1, F. Mansour1, M. Mukhtar2, B. El-Sayed1
1 Tropical Medicine Research Institute, Khartoum, Sudan
2 Institute of Endemic Diseases, University of Khartoum,
Khartoum, Sudan
Backgroud: Malaria is an important cause of mor-
bidity,however not everyone infected with the parasite
develops clinical symptoms. Naturally acquired immunity to
malaria varies considerably between geographical regions
due to different parasite strains and transmission intensi-
ties which affect the selection of vaccine targets. Merozoite
surface protein 3 (MSP3) is a polymorphic antigen induces
immune response. This study measured the presence of anti-
bodies to P. falciparum MSP3 recombinant antigen in plasma
from asymptomatic individuals in relation to protection from
malaria during the transmission season.
Methods: The study was conducted in an area of seasonal
transmission on a cohort of 114 asymptomatic sub-patent P.
falciparum carriers who were examined for the presence
of IgG, IgG1 and IgG3 by ELISA. The cohort was treated
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in the pre-transmission season (August 2004) with Arte-
sunate + Sulphadoxine/Pyrimethamine and followed for 14
days. They were screened for malaria in the following
transmission season (October 2004). Further samples were
collected in October 2006.
Results: Detected anti-MSP3 antibodies on Day0 of treat-
ment were 41%, 20% and 12% for IgG, IgG1 and IgG3
respectively. Positive percentage on Day14 after treatment
were 25%, 12% and 9% for IgG, IgG1 and IgG3 respectively
and in 2006 were 33.3%, 21% and 6% for IgG, IgG1 and IgG3
respectively. Twenty six and 16 individuals had IgG1 or IgG3
or both on Day0 and Day14 respectively, all of them were
slide negative in the next transmission season. In October
2006, 24 had IgG1 or IgG3 or both, 19 were slide negative.
Conclusion: Pre-season treatment has no signiﬁcant
effect on the number of reactive antibodies (p > 0.05). There
was no signiﬁcant association between IgG presence and
malaria infection in 2006 (p > 0.05), despite approximately
same IgGs positivity in 2004. Anti-MSP3 IgG1 and IgG3 could
contribute to the persistence of asymptomatic low para-
sitaemia during the dry season. Different epitopes between
recombinant and natural MSP3 antigen stimulate different
IgGs response. That should be considered when assessing
vaccine trails.
doi:10.1016/j.ijid.2008.05.832
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Determination of Parasite Clearance Time in Antimalarial
Drug Trials Using Real-Time Quantitative PCR (PCR)
C.E. Oriero ∗, D. Nwakanma, S. Sesay, D. Conway
Medical Research Council Laboratories, Fajara, Gambia
Microscopy is generally relied upon for malaria diag-
nosis and determination of parasite density. However in
drug efﬁcacy trials where high throughput screening is
required, microscopy is slow, labour intensive and unable
to detect low-grade infections reliably. Estimation of par-
asite density in antimalarial drug trials is important as
endpoints such as time to parasite clearance or percentage
reduction in the initial parasitaemia level allows compar-
ison of the efﬁcacy of different drug combinations. In
this study, Real-time Quantitative PCR (qPCR) was used to
determine parasite clearance time in an efﬁcacy trial of
two antimalarial drugs, Artemether-Lumefantrine combina-
tion (Coartem®) and Pyronaridine-Artesunate combination
(Pyramax®). Blood samples were collected at 8-hourly inter-
vals following treatment from each of the 106 patients
enrolled in the study. The resulting 10 samples per patient
collected over a 3-day period were analyzed by qPCR ampli-
ﬁcation of the 18SrDNA gene to determine the time to
parasite clearance. The results indicate that low-grade par-
asitaemia (<20 parasites/L) was still detectable by qPCR in
20% of the patients up to 24 hours after they were negative
by microscopy. Our results indicate that the application of
a more sensitive parasite detection method such as qPCR,
could lead to more precise determination of the relative
efﬁcacy of antimalarial drugs.
doi:10.1016/j.ijid.2008.05.833
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Peritoneal Dialysis: A Life Saving Intervention for Acute
Renal Failure from Falciparum Malaria in a Secondary Care
Setting
A. Singh ∗, D. Singh, P. Singh
Baptist Christian Hospital, Tezpur, India
Background: The mortality associated with severe
malaria remains high in malaria endemic regions due to
the non availability of sophisticated intensive care facilities
and limited resources. Acute renal failure from falciparum
malaria requiring renal replacement therapy portends a
grave prognosis in rural India. In a low resource country like
ours hemodialysis facilities are found only in tertiary care
centres which are inaccessible to the majority of people who
suffer from this disease.
Objective: To describe peritoneal dialysis as a relevant
alternative to hemodialysis in a secondary care setting
in rural India. Materials and methods: Case series of 13
patients admitted to the Baptist Christian hospital with
severe malaria requiring dialysis.
Results: Thirteen patents underwent peritoneal dialysis
for acute renal failure resulting from falciparum malaria. 10
were between 18—45 years of age and three were below 12
years of age. 11 had falciparum malaria while 2 had mixed
falciparum and vivax malaria. 10 were oliguric. Serum cre-
atinine levels ranged between 2.8mg% to 23.4mg%. 9 had
cerebral involvement and 9 had jaundice. Seven patients
had elevated transaminases of which ﬁve had levels more
than 200. All but one had AST more than ALT. 8 patients
had Hb less than 7 gms of which four were less than 5 gms.
10 patients had respiratory distress. All adult patients were
treated with artesunate and doxycycline, artesunate and
clindamycin were used in the pediatric age group. Continu-
ous peritoneal dialysis was carried out for an average of 4.7
days. One peritoneal dialysis was complicated by peritonitis
which resolved with antibiotics. 11 patients recovered com-
pletely while two succumbed to the disease within 24 and
48 hours of admission.
Conclusion: Peritoneal dialysis can be a life saving inter-
vention for patients with severe malaria in a secondary care
centre in rural India.
doi:10.1016/j.ijid.2008.05.834
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Production and Modiﬁcation of Human Monoclonal Anti-
body Fab Fragments to the 19-Kilodalton C-Terminal
Merozoite Surface Protein 1 of Plasmodium falciparum
H. Tachibana1,∗, X. Cheng2, Y. Tao2, Y. Fu2, E. Yoshihara1,
K. Tanabe3
1 Tokai University School of Medicine, Isehara, Japan
2 Fudan University School of Medicine, Shanghai, China
3 Research Institute for Microbial Diseases, Osaka Univer-
sity, Osaka, Japan
An effective vaccine for malaria has not yet been
developed. Passive immunotherapy with human monoclonal
antibodies may provide a valuable therapeutic alterna-
tive. A combinatorial immunoglobulin gene library was
